National Comprehensive Cancer Network

NCCN Oncology Research Program (ORP)
NCCN ORP Recent News
NCCN ORP Affiliate Research Consortium
NCCN ORP Scientific Publications
NCCN ORP for Industry
NCCN ORP Investigator Steering Committee
NCCN ORP Testimonials
NCCN Clinical Trials at NCCN Member Institutions
Find NCCN ORP Funded Clinical Trials at NCCN Member Institutions
NCCN ORP Grant History
NCCN Informed Consent Language Database
NCCN Specialized Imaging Research Consortium™ (SIRC)
NCCN ORP Disclosure Policy
NCCN Collaboration with the National Business Group on Health
NCCN Health Information Technology Licensees

NCCN Research & Business Resources

NCCN Guidelines for Kidney Cancer Updated to Include Pazopanib for Advanced Disease

The NCCN Clinical Practice Guidelines in Oncology™ for Kidney Cancer have been updated to incorporate the recently approved therapy pazopanib as a treatment option for patients with advanced renal cell carcinoma.

The NCCN Guidelines Panel for Kidney Cancer has added pazopanib as a first-line therapy option for those with predominant clear cell histology (category 1 designation) and for those with non clear cell histology (category 3 designation). In addition, pazopanib has been incorporated into the options for subsequent therapy for those with predominant clear cell histology following cytokine therapy (category 1 designation) and following other tyrosine kinase inhibitors (category 3 designation).